The identification of PDAC patient subgroups that benefit from the application of PD-1 or PD-L1 blocking antibodies is not only the key to an effective therapy concept, but also essential for the understanding of tumor biology and treatment adaption in the course of tumor progression. The gene discussed is PDCD1; the disease is neoplasm.